Management of Hyperglycemia in Type 2 Diabetes: A Summary of New Consensus Report from the American Diabetes Association and the European Association for the Study of Diabetes in 2018 / 임상당뇨병
Journal of Korean Diabetes
;
: 6-9, 2019.
Article
in Korean
| WPRIM
| ID: wpr-761472
ABSTRACT
In 2018, the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) published a consensus recommendation on management of hyperglycemia. This consensus report emphasized the need for patient-centered management considering multimorbidity and individual patient preferences and barriers. Patients with type 2 diabetes with established atherosclerotic cardiovascular disease who fail to control blood glucose with the initial glucose-lowering medication are recommended a sodium-glucose cotransporter 2 (SGLT2) inhibitor or a glucagon-like peptide 1 (GLP-1) receptor agonist. For patients with chronic kidney disease and heart failure, SGLT2 inhibitors are recommended. In patients who need an injectable medication, GLP-1 receptor agonists are the preferred choice over insulin. In this section, we summarize “Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).”
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Blood Glucose
/
Cardiovascular Diseases
/
Comorbidity
/
Patient-Centered Care
/
Consensus
/
Diabetes Mellitus
/
Renal Insufficiency, Chronic
/
Atherosclerosis
/
Glucagon-Like Peptide 1
/
Patient Preference
Type of study:
Practice guideline
Limits:
Humans
Language:
Korean
Journal:
Journal of Korean Diabetes
Year:
2019
Type:
Article
Similar
MEDLINE
...
LILACS
LIS